Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Seattle Genetics Signs U.K. Partner

September 19, 2011 | A version of this story appeared in Volume 89, Issue 38

Seattle Genetics and Oxford BioTherapeutics will jointly discover antibody-drug conjugates for cancer. OBT will generate panels of monoclonal antibodies against tumor-specific antigens that will be screened for activity using Seattle Genetics’ technology. The companies will each have an equal number of alternating options to select resulting antibody-drug conjugates for further development. Each company will receive progress-dependent milestone payments and royalties on sales of any resulting products by the other partner.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.